Randomized Anticoagulation Trial In Opcab HIGH DOSE VERSUS LOW DOSE HEPARINIZATION IN PATIENTS - Randomized Anticoagulation Trial In Opcab

AZIENDA SOCIO-SANITARIA TERRITORIALE DI LECCO (ASST LECCO)0 sites900 target enrollmentSeptember 7, 2021

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Off-pump coronary artery bypass grafting (OPCAB) is an established alternative to on-pump coronary artery bypass grafting (CABG),OPCAB, like any other surgical procedure, determines a pro-coagulant state potentially deleterious on grafts patency, that is not counterbalanced by the adverse effects of cardiopulmonary bypass on coagulation occurring in CABG, and that lasts as long as one month. Therefore systemic heparinization is necessary in OPCAB to prevent thrombotic complications during trans
Sponsor: AZIENDA SOCIO-SANITARIA TERRITORIALE DI LECCO (ASST LECCO)
Enrollment: 900
Status: Active, not recruiting
Last Updated: 4 years ago

No summary available.

Registry

who.int

Start Date

September 7, 2021

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

AZIENDA SOCIO-SANITARIA TERRITORIALE DI LECCO (ASST LECCO)

•All consecutive patients undergoing elective multivessel OPCAB, aged \>18 years, of both sexes
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 300
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range 600

•Exclusion criteria are represented by the diagnosis of acute coronary syndrome, on\-going double anti\-platelets treatment (the second antiplatelet drug should be suspended 5 days before surgery), on\-going intravenous heparinization or sub\-cutaneous low molecular weight heparin (LMWH), known coagulopathy, documented liver disease, chronic renal failure (creatinine \= 2 mg/dl) or previous renal transplantation surgery, previous cardiac surgery.